Corbus Pharmaceuticals Holdings, Inc. has made headlines with the announcement of favorable results from its CANYON-1 Phase 1b clinical trial for CRB-913, a treatment aimed at obesity. The data, presented at ObesityWeek® 2026, indicates that all three doses of CRB-913 led to statistically significant weight loss, with the highest dose achieving a mean weight loss of 5% at 12 weeks. This development is particularly significant as it underscores Corbus's potential to establish a new class of oral, non-incretin obesity medicines.
The results also highlighted a favorable safety and tolerability profile for CRB-913, with a low treatment discontinuation rate of 8.3% due to adverse events, aligning with existing data for GLP-1 medications. Notably, treatment-emergent psychiatric adverse events were infrequent and mild, with no serious cases reported. This information positions CRB-913 as a strong contender in the obesity treatment market, which is increasingly competitive.
Corbus Pharmaceuticals Holdings, Inc., incorporated in Delaware, operates in the pharmaceutical preparations sector (SIC 2834) and is listed on the Nasdaq under the ticker CRBP. The company has been active in filing various reports, including recent 8-K forms, with the latest being filed on November 16, 2026, which detailed the trial results.
According to the SEC filing (accession number 0001193125-26-462186), the company shared that additional data from the CANYON-1 trial were presented in a poster format at the ObesityWeek® 2026 event held in Washington, D.C. This event is significant for the field of obesity research and treatment, providing a platform for companies to showcase their latest findings.
Corbus's trial results could have implications for various stakeholders, including healthcare providers, patients seeking obesity treatments, and investors in the pharmaceutical sector. The positive outcomes may influence prescribing practices and patient choices, while also attracting attention from industry competitors who are keen to understand the evolving landscape of obesity treatment options.
Looking ahead, Corbus Pharmaceuticals has not specified what steps will follow this announcement. However, the positive trial results may lead to further clinical trials or discussions with regulatory bodies regarding the next phases of development for CRB-913. The filing does not indicate any immediate next steps, leaving the market to speculate on the implications of these results.
Read Next
Kaltenbach acquires 534 shares in Mettler Toledo
Keller Gerry Acquires Shares in Mettler Toledo
CFO Shawn Vadala acquires 176 shares in Mettler Toledo
Eli Samaha discloses sale of 9.2 million Theravance shares
Davion Healthcare to Acquire Independence Care Network
Tompkins Financial updates on conference participation





